KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Cash (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Change in Cash for 8 consecutive years, with $31.2 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 25.95% to $31.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, down 114.28% year-over-year, with the annual reading at -$3.0 million for FY2025, 114.28% down from the prior year.
  • Change in Cash hit $31.2 million in Q4 2025 for Castle Biosciences, up from $3.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $31.2 million in Q4 2025 to a low of -$139.0 million in Q3 2022.
  • Historically, Change in Cash has averaged -$14.7 million across 5 years, with a median of -$7.8 million in 2023.
  • Biggest five-year swings in Change in Cash: tumbled 2592.48% in 2022 and later skyrocketed 301.83% in 2024.
  • Year by year, Change in Cash stood at -$33.5 million in 2021, then soared by 66.52% to -$11.2 million in 2022, then surged by 167.82% to $7.6 million in 2023, then surged by 224.89% to $24.8 million in 2024, then grew by 25.95% to $31.2 million in 2025.
  • Business Quant data shows Change in Cash for CSTL at $31.2 million in Q4 2025, $3.3 million in Q3 2025, and -$7.5 million in Q2 2025.